Replimune (REPL) Preferred Stock Liabilities (2018)

Replimune (REPL) reported Preferred Stock Liabilities of $86.4 million for Q2 2018, little changed sequentially from $86.4 million in Q1 2018.

Replimune (REPL) Preferred Stock Liabilities (2018) Analysis & Trends

Replimune (REPL) has 1 years of Preferred Stock Liabilities data on file, last reported at $86.4 million in Q2 2018.

For the quarter ending Q2 2018, Preferred Stock Liabilities changed N/A year-over-year to $86.4 million; the trailing twelve-month figure through Jun 2018 stood at $86.4 million (changed N/A YoY), and the FY2018 full-year result was $86.4 million, changed N/A from the prior year.
Preferred Stock Liabilities was little changed at $86.4 million in Q2 2018, from $86.4 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $86.4 million in Q1 2018 to a low of $86.4 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Replimune	970.73 Mn	970.73 Mn	-	-

Download Data

Date	Value
Jun 30, 2018	86.36 Mn
Mar 31, 2018	86.36 Mn